Methods of treating overweight and obesity

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.

Compositions And Methods For Reducing Major Adverse Cardiovascular Events

The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or MACE, wherein the treatment reduces the risk of MACE.

Compositions and methods for weight loss in at risk patient populations

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.

Methods of treating overweight and obesity

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.

METHODS OF TREATING OVERWEIGHT AND OBESITY

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes. 1. A method of treating a subject at increased risk of an adverse cardiovascular outcome comprising for overweight or obesity:identifying an overweight or obese subject at increased risk of an adverse cardiovascular outcome; andadministering to said subject a therapeutically effective amount of sustained release naltrexone, or a pharmaceutically acceptable salt thereof, and sustained release bupropion, or a pharmaceutically acceptable salt thereof.235-. (canceled) The present application is a continuation of U.S. application Ser. No. 14/405,775, which is the U.S. National Phase under 35 U.S.C. § 371 of International Application No. PCT/US2013/044368, entitled “METHODS OF TREATING OVERWEIGHT AND OBESITY,” filed Jun. 5. 2013, and published in English on Dec. 12, 2013 as WO 2013/184837, which is a non-provisional of and claims priority to U.S. Provisional Application No. 61/656,451 filed on Jun. 6, 2012, which, where permitted, is herein incorporated by reference in its entirety.The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and optionally in subjects at increased risk of adverse cardiovascular outcomes.Obesity has been defined in terms of body mass index (BMI). BMI is calculated as weight (kg)/[height (m)]. According to the guidelines of the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), for adults over 20 years old, BMI is categorized as follows: below 18.5 is considered underweight, ...

Exendins To Lower Cholesterol And Triglycerides

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microshperes encapsulating the exenatide.

Compositions and methods for reducing major adverse cardiovascular events

The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable alts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovasular outcomes or MACE, wherein the treatment reduce, the risk of MACE.

Methods for treating diabetes and reducing body weight

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA 1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

Compositions and methods for reducing major adverse cardiovascular events

The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or MACE, wherein the treatment reduces the risk of MACE.

METHODS OF TREATING OVERWEIGHT AND OBESITY

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes. 1. A method of treating a subject at increased risk of an adverse cardiovascular outcome comprising for overweight or obesity:identifying an overweight or obese subject at increased risk of an adverse cardiovascular outcome; andadministering to said subject a therapeutically effective amount of sustained release naltrexone, or a pharmaceutically acceptable salt thereof, and sustained release bupropion, or a pharmaceutically acceptable salt thereof.2. The method of claim 1 , wherein said overweight or obese subject is identified as being at increased risk of an adverse cardiovascular outcome if said subject: a history of documented myocardial infarction >3 months prior to said identification;', 'a history of coronary revascularization including coronary artery bypass graft surgery, stent placement, percutaneous transluminal coronary angioplasty, or laser atherectomy;', 'a history of carotid or peripheral revascularization, including carotid endarterectomy, lower extremity atherosclerotic disease atherectomy, repair of abdominal aorta aneurysm, femoral or popliteal bypass;', 'angina with ischemic changes, ECG changes on a graded exercise test, or positive cardiac imaging study;', 'ankle brachial index <0.9 assessed by simple palpation within prior 2 years of said identification; and', '≧50% stenosis of a coronary, carotid, or lower extremity artery within prior 2 years of said identification;, 'a.) is diagnosed as having cardiovascular disease with at least one risk factor selected from the group consisting ofand/or hypertension controlled with or without pharmacotherapy at <145/95 mm Hg;', 'dyslipidemia requiring pharmacotherapy;', ' ...

Methods Of Treating Overweight And Obesity

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.

Methods of treating overweight and obesity

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.

Anchor delivery system

A system and associated method for manipulating tissues and anatomical or other structures in medical applications for the purpose of treating diseases or disorders or other purposes. In one aspect, the system includes a delivery device configured to deploy and implant anchor devices for such purposes.

METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbAand reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided. 1. A method for treating type 2 diabetes in a human in need thereof , the method comprising administering to the human an effective amount of a sustained release pharmaceutical composition comprising 5% (w/w) exendin-4 , 2% (w/w) sucrose , and 93% (w/w) poly(lactide-co-glycolide)copolymer to achieve a mean steady state plasma concentration of the exendin-4 of at least 200 pg/ml for at least one month in the human to treat type 2 diabetes.2. The method of claim 1 , wherein the sustained release pharmaceutical composition is administered in a continuous mode.3. The method of claim 2 , wherein the continuous mode results from administering the sustained release composition once weekly by subcutaneous injection.4. The method of claim 1 , wherein the poly(lactide-co-glycolide) copolymer is purified 50:50 (lactide:glycolide) poly(D claim 1 ,L-lactide-co-glycolide).5. The method of claim 1 , wherein the sustained minimum plasma concentration of the exendin-4 is between 200 pg/ml to 350 pg/ml.6. The method of claim 1 , wherein the exendin-4 is co-administered with metformin claim 1 , a sulphonylurea claim 1 , a thiazolidinedione or any combination thereof.7. The method of claim 3 , wherein 2 mg of the exendin-4 is administered once weekly.8. A method for reducing HbA1C claim 3 , fasting plasma glucose claim 3 , or body weight in a human in need thereof claim 3 , the method comprising administering to the human in a continuous mode an effective amount of a sustained release pharmaceutical composition comprising 5% (w/w) exendin-4 claim 3 , 2% (w/w) sucrose claim 3 , and 93% (w/w) poly(lactide-co-glycolide)copolymer in an amount to achieve a mean steady state concentration of exendin-4 of at least 200 pg/ml for at least one month to reduce HbA1C claim 3 , fasting ...

Methods for Treating Diabetes and Reducing Body Weight

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbAand reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided. 1. A method for treating diabetes in a human in need thereof comprising administering once weekly to the human a therapeutically effective amount of a pharmaceutical composition comprising exendin-4 or an exendin analog to achieve a mean steady state plasma concentration of the exendin-4 or the exendin-4 analog of at least 170 pg/ml for at least one month in the human to treat diabetes.2. The method of claim 1 , wherein the pharmaceutical composition comprises exendin-4.3. The method of claim 1 , wherein the pharmaceutical composition comprises the exendin analog.4. The method of claim 3 , wherein the exendin analog comprises the amino acid sequence of any one of SEQ ID NOs: 2 and 9-142.5. The method of claim 1 , wherein the pharmaceutical composition further comprises a poly(lactide-co-glycolide) copolymer.6. The method of claim 2 , wherein the pharmaceutical composition further comprises a sugar.7. The method of claim 1 , wherein the exendin-4 or the exendin analog is present in the pharmaceutical composition in an amount of 1.0 mg to 5.0 mg.8. The method of claim 1 , wherein the pharmaceutical composition comprises 5% (w/w) exendin-4 claim 1 , 2% (w/w) sucrose claim 1 , and 93% (w/w) poly(lactide-co-glycolide)copolymer.9. The method of claim 1 , wherein the mean steady state plasma concentration of exendin-4 or the exendin analog is 170 pg/ml to 600 pg/ml.10. The method of claim 1 , wherein the mean steady state plasma concentration of exendin-4 or the exendin analog is 170 pg/ml to 350 pg/ml.11. The method of claim 1 , wherein the mean steady state plasma concentration of exendin-4 or the exendin analog is 170 pg/ml to 290 pg/ml.12. The method of claim 1 , wherein the diabetes is type 2 diabetes.13. The method of claim 1 , wherein the diabetes is type ...

COMPOSITIONS AND METHODS FOR WEIGHT LOSS IN AT RISK PATIENT POPULATIONS

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes. 1. A method of treating a subject for overweight or obesity , comprising:selecting for treatment an overweight or obese subject at increased risk of a major adverse cardiovascular event that (a) has had type-two diabetes for a period of less than 6 years, or (b) is a current smoker that does not have type-two diabetes; andtreating the subject for overweight or obesity by administering to the subject a daily dose of 32 mg of sustained release naltrexone, or a pharmaceutically acceptable salt thereof and 360 mg bupropion, or a pharmaceutically acceptable salt thereof, for a period of at least 12 weeks, wherein said administering reduces the risk of a major adverse cardiovascular event in said overweight or obese subject.2. The method of claim 1 , wherein the subject was administered:about 8 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 90 mg of said sustained release bupropion or a pharmaceutically acceptable salt thereof daily for a first week of treatment;about 16 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 180 mg of said sustained release bupropion or a pharmaceutically acceptable salt thereof daily for a second week of treatment;about 24 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 270 mg of said sustained release bupropion or a pharmaceutically acceptable salt thereof daily for a third week of treatment; andabout 32 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 360 mg of said sustained release ...

Method for treating diabetes

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

Method of lowering cholesterol and triglycerides by administering exendins

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide ...

Median Lobe Retraction Apparatus and Method

A system and associated method for manipulating tissues and anatomical or other structures in medical applications for the purpose of treating diseases or disorders or other purposes. In one aspect, the system includes a delivery device configured to deploy and implant anchor devices for comprising, distracting and/or retracting the lobes of a prostate.

COMPOSITIONS AND METHODS FOR WEIGHT LOSS IN AT RISK PATIENT POPULATIONS

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes. 1. A method of treating a subject for overweight or obesity , comprising:selecting an overweight or obese subject at increased risk of adverse cardiovascular outcomes that has had type-two diabetes for a period of less than 6 years; andtreating the subject for overweight or obesity by administering to the subject a daily dose of 32 mg of sustained release naltrexone, or a pharmaceutically acceptable salt thereof and 360 mg bupropion, or a pharmaceutically acceptable salt thereof, for a period of at least 12 weeks.2. A method of treating a subject for overweight or obesity , comprising:selecting an overweight or obese subject at increased risk of adverse cardiovascular outcomes that is a current smoker that does not have type-two diabetes; andtreating the subject for overweight or obesity by administering to the subject a daily dose of 32 mg of sustained release naltrexone and 360 mg bupropion, or a pharmaceutically acceptable salts thereof, for a period of at least 12 weeks.3. The method of claim 1 , wherein the subject was administered:about 8 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 90 mg of said sustained release bupropion or a pharmaceutically acceptable salt thereof daily for a first week of treatment;about 16 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 180 mg of said sustained release bupropion or a pharmaceutically acceptable salt thereof daily for a second week of treatment;about 24 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 270 mg of ...

Compositions and methods for weight loss in at risk patient populations

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.

Compositions and methods for weight loss in at risk patient populations

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.

EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide. 119.-. (canceled)20. A method for treating dyslipidemia or atherosclerosis in a human in need thereof comprising:identifying a human in need of a treatment for dyslipidemia or atherosclerosis; andadministering to the human a pharmaceutical formulation comprising at least one exendin or exendin analog agonist once per week in an amount sufficient to maintain a steady state geometric mean plasma concentration of the exendin or exendin analog agonist of 145 pg/mL to 700 pg/mL to treat the dyslipidemia or atherosclerosis in the patient, wherein the amount is about 2.0 mg to about 5 mg, and wherein a dosage of the formulation comprises about 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer.21. The method of claim 20 , wherein the exendin or exendin analog agonist is (i) exendin-4 or (ii) a peptide having at least 90% sequence identity to exendin 4.22. The method of claim 20 , wherein the steady state geometric mean plasma ...

ANCHOR DELIVERY SYSTEM

A system and associated method for manipulating tissues and anatomical or other structures in medical applications for the purpose of treating diseases or disorders or other purposes. In one aspect, the system includes a delivery device configured to deploy and implant anchor devices for such purposes.

Compositions And Methods For Weight Loss In At Risk Patient Populations

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes. 1. A method of treating a subject for overweight or obesity , comprising:selecting an overweight or obese subject at increased risk of adverse cardiovascular outcomes that has had type-two diabetes for a period of less than 6 years; andtreating the subject for overweight or obesity by administering to the subject a daily dose of 32 mg of sustained release naltrexone, or a pharmaceutically acceptable salt thereof and 360 mg bupropion, or a pharmaceutically acceptable salt thereof, for a period of at least 12 weeks.2. A method of treating a subject for overweight or obesity , comprising:selecting an overweight or obese subject at increased risk of adverse cardiovascular outcomes that is a current smoker that does not have type-two diabetes; andtreating the subject for overweight or obesity by administering to the subject a daily dose of 32 mg of sustained release naltrexone and 360 mg bupropion, or a pharmaceutically acceptable salts thereof, for a period of at least 12 weeks.3. The method of claim 1 , wherein the subject was administered:about 8 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 90 mg of said sustained release bupropion or a pharmaceutically acceptable salt thereof daily for a first week of treatment;about 16 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 180 mg of said sustained release bupropion or a pharmaceutically acceptable salt thereof daily for a second week of treatment;about 24 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 270 mg of ...

ANCHOR DELIVERY SYSTEM

A system and associated method for manipulating tissues and anatomical or other structures in medical applications for the purpose of treating diseases or disorders or other purposes. In one aspect, the system includes a delivery device configured to deploy and implant anchor devices for such purposes. 1. A system for treatment of body tissue , comprising:an anchor assembly, the anchor assembly including a first component attached to a connector and a second anchor component; anda delivery device, the delivery device including a handle, an elongate portion extending from the handle, the elongate portion including a leading end, a needle tube, and a scope assembly, a needle assembly extending through the needle tube and configured to be advanced from the leading end, and the connector extending through the needle assembly;wherein the leading end includes a needle targeting structure configured to facilitate targeting the needle through tissue.2. The system of claim 1 , wherein a terminal end of the needle assembly has a start position within view of the scope assembly.3. The system of claim 1 , wherein the leading end is configured with a guide to constrain the needle assembly to exit the leading end in a generally perpendicular direction with respect to the elongate portion.4. The system of claim 1 , wherein the needle assembly has a start position in a path of the second anchor component.5. The system of claim 1 , wherein the needle has a beveled tip on another side of the needle assembly from that of an inside radius as it is ejected from the delivery device.6. The system of claim 1 , wherein the scope assembly is laterally offset from the needle tube.7. The system of claim 6 , wherein one or more of the scope assembly and needle assembly are configured to be laterally translated.8. The system of claim 1 , wherein the scope assembly is configured to be translated axially.9. The system of claim 1 , further comprising a cover claim 1 , wherein the cover is ...

Compositions And Methods For Reducing Major Adverse Cardiovascular Events

The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable alts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovasular outcomes or MACE, wherein the treatment reduce, the risk of MACE. 1. A method of treating a subject at increased risk of major adverse cardiovascular event (MACE) comprising:selecting for treatment a subject at increased risk of MACE; andadministering to said subject an amount of naltrexone, or a pharmaceutically acceptable salt thereof and bupropion, or a pharmaceutically acceptable salt thereof, effective to reduce said increased risk.246-. (canceled) The present application claims the benefit of priorities to U.S. Appl. Nos. 61/913,216, filed Dec. 6, 2013; 61/914,938, filed Dec. 11, 2013; 61/984,580, filed Apr. 25, 2014, and Ser. No. 14/322,810, filed Jul. 2, 2014, each of which is hereby incorporated by references in its entirety.Cardiovascular disease (“CVD”), which includes heart disease, is a class of diseases that involve the heart, the blood vessels (arteries, capillaries, and veins) or both. Cardiovascular disease refers to any disease that affects the cardiovascular system, principally cardiac disease, vascular diseases of the brain and kidney, and peripheral arterial disease. The causes of cardiovascular disease are diverse but atherosclerosis and/or hypertension are the most common.Cardiovascular disease is the number one cause of death worldwide. Accordingly to WHO March 2013 Fact Sheet ...

COMPOSITIONS AND METHODS FOR WEIGHT LOSS IN AT RISK PATIENT POPULATIONS

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes. 1. A method of treating a subject for overweight or obesity , comprising:selecting an overweight or obese subject at increased risk of adverse cardiovascular outcomes that has had type-two diabetes for a period of less than 6 years; andtreating the subject for overweight or obesity by administering to the subject a daily dose of 32 mg of sustained release naltrexone, or a pharmaceutically acceptable salt thereof and 360 mg bupropion, or a pharmaceutically acceptable salt thereof, for a period of at least 12 weeks.2. A method of treating a subject for overweight or obesity , comprising:selecting an overweight or obese subject at increased risk of adverse cardiovascular outcomes that is a current smoker that does not have type-two diabetes; andtreating the subject for overweight or obesity by administering to the subject a daily dose of 32 mg of sustained release naltrexone and 360 mg bupropion, or a pharmaceutically acceptable salts thereof, for a period of at least 12 weeks.3. The method of claim 1 , wherein the subject was administered:about 8 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 90 mg of said sustained release bupropion or a pharmaceutically acceptable salt thereof daily for a first week of treatment;about 16 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 180 mg of said sustained release bupropion or a pharmaceutically acceptable salt thereof daily for a second week of treatment;about 24 mg of said sustained release naltrexone or a pharmaceutically acceptable salt thereof and about 270 mg of ...

Methods for treating diabetes and reducing body weight

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

ANCHOR DELIVERY SYSTEM

A system and associated method for manipulating tissues and anatomical or other structures in medical applications for the purpose of treating diseases or disorders or other purposes. In one aspect, the system includes a delivery device configured to deploy and implant anchor devices for such purposes. 1. A system for treatment of body tissue , comprising:an anchor assembly, the anchor assembly including a first component attached to a connector and a second anchor component; anda delivery device, the delivery device including a handle, an elongate portion extending from the handle, the elongate portion including a leading end, a needle tube, and a scope assembly, a needle assembly extending through the needle tube and configured to be advanced from the leading end, and the connector extending through the needle assembly;wherein a terminal end of the needle assembly has a start position within view of the scope assembly and within the leading end of the elongate portion.2. (canceled)3. The system of claim 1 , wherein the leading end is configured with a guide to constrain the needle assembly to exit the leading end in a generally perpendicular direction with respect to the elongate portion.4. The system of claim 1 , wherein the needle assembly has a start position in a path of the second anchor component.5. The system of claim 1 , wherein the needle has a beveled tip on another side of the needle assembly from that of an inside radius as it is ejected from the delivery device.6. The system of claim 1 , wherein the scope assembly is laterally offset from the needle tube.7. The system of claim 6 , wherein one or more of the scope assembly and needle assembly are configured to be laterally translated.8. The system of claim 1 , wherein the scope assembly is configured to be translated axially.9. The system of claim 1 , further comprising a cover claim 1 , wherein the cover is positioned between the needle tube and scope assembly.10. The system of claim 1 , wherein a ...

EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microshperes encapsulating the exenatide ...

METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

Median lobe retraction apparatus and method

A system and associated method for manipulating tissues and anatomical or other structures in medical applications for the purpose of treating diseases or disorders or other purposes. In one aspect, the system includes a delivery device configured to deploy and implant anchor devices for comprising, distracting and/or retracting the lobes of a prostate.

COMPOSITIONS AND METHODS FOR REDUCING MAJOR ADVERSE CARDIOVASCULAR EVENTS

The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or MACE, wherein the treatment reduces the risk of MACE. 1. A method of treating a subject at increased risk of major adverse cardiovascular event (MACE) comprising:selecting for treatment a subject at increased risk of MACE; andadministering to said subject an amount of naltrexone, or a pharmaceutically acceptable salt thereof and bupropion, or a pharmaceutically acceptable salt thereof, effective to reduce said increased risk.2. The method of claim 1 , wherein the subject has one or more of the following characteristics at the time of treatment: Type II diabetes; existing cardiovascular disease or a high likelihood of cardiovascular disease; congestive heart failure; family history of cardiovascular disease; current smoker; genetically predisposed to cardiovascular diseases; has or has had cardiac arrhythmia; has or has had atrial fibrillation claim 1 , ventricular fibrillation claim 1 , or tachyarrhythmia; does not have sinus tachycardia; has unstable angina; has hypertension; has had a stroke or is at increased risk of stroke; has an aneurysm; or has elevated triglycerides claim 1 , elevated LDL claim 1 , and/or low HDL.3. The method of claim 2 , wherein the subject has type 2 diabetes or a confirmed diagnosis of cardiovascular disease.4. The method of claim 2 , wherein the subject has ...

Compositions and methods for weight loss in at risk patient populations

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.

Median lobe retraction apparatus and method

A system and associated method for manipulating tissues and anatomical or other structures in medical applications for the purpose of treating diseases or disorders or other purposes. In one aspect, the system includes a delivery device configured to deploy and implant anchor devices for comprising, distracting and/or retracting the lobes of a prostate.

INTERNAL BOTTLE ADAPTER FOR MATERIAL TRANSFER

An adapter for accessing material in a container may include an adapter body with a bore through its longitudinal axis. The adapter may include one or more sealing surfaces and a threaded connection nested in the adapter body. The threaded connection may be configured to mate with an CORPAK ENFIT connection or a luer lock connection. 1. An adapter , comprising:an adapter body having a bore relative to a longitudinal axis thereof;one or more sealing surfaces connected to the adapter body and having a sealing surface diameter; anda threaded connection nested in the adapter body.2. The adapter of claim 1 , further comprising an upper surface having an upper surface diameter claim 1 , wherein the upper surface diameter is greater than the sealing surface diameter.3. The adapter of claim 1 , wherein the adapter body is tapered.4. The adapter of claim 1 , wherein the one or more sealing surfaces have different sealing surface diameters.5. The adapter of claim 1 , wherein the threaded connection mates with a luer lock connection.6. The adapter of claim 1 , wherein the threaded connection mates with a CORPAK ENFIT connection.7. The adapter of claim 1 , further comprising a directional air valve.8. A system for accessing material in a container claim 1 , comprising:a container having an opening with an opening diameter, the container including material; and an adapter body having a bore relative to a longitudinal axis thereof;', 'one or more sealing surfaces connected to the adapter body, wherein at least one of the one or more sealing surfaces has a sealing surface diameter that is at least as large as the opening diameter; and', 'a threaded connection nested in the adapter body., 'an adapter, the adapter including9. The system of claim 8 , further comprising a material transfer device having a connector complementary to the threaded connection.10. The system of claim 9 , wherein the material transfer device is gravity fed.11. The system of claim 9 , wherein the material ...

METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbAand reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided. 1133-. (canceled)134. A method for treating diabetes in a human in need thereof , the method comprising administering once monthly to the human an effective amount of a pharmaceutical composition comprising exendin-4 or an exendin analog to achieve a mean steady state plasma concentration of the exendin-4 or the exendin-4 analog at least 170 pg/ml for at least one month in the human to treat diabetes.135. The method of claim 134 , wherein the pharmaceutical composition comprises exendin-4.136. The method of claim 134 , wherein the pharmaceutical composition comprises the exendin analog.137. The method of claim 136 , wherein the exendin analog comprises the amino acid sequence of any one of SEQ ID NOs: 2 and 9-142.138. The method of claim 134 , wherein the pharmaceutical composition further comprises a sugar.139. The method of claim 134 , wherein the pharmaceutical composition further comprises a poly(lactide-co-glycolide) copolymer.140. The method of claim 139 , wherein the poly(lactide-co-glycolide) copolymer is purified 50:50 (lactide:glycolide) poly(D claim 139 ,L-lactide-co-glycolide).141. The method of claim 134 , wherein the pharmaceutical composition comprises 5% (w/w) exendin-4 claim 134 , 2% (w/w) sucrose claim 134 , and 93% (w/w) poly(lactide-co-glycolide)copolymer.142. The method of claim 134 , wherein the mean steady state plasma concentration of exendin-4 or the exendin analog is 170 pg/ml to 600 pg/ml.143. The method of claim 134 , wherein the mean steady state plasma concentration of exendin-4 or the exendin analog is 170 pg/ml to 350 pg/ml.144. The method of claim 134 , wherein the mean steady state plasma concentration of exendin-4 or the exendin analog is 170 pg/ml to 290 pg/ml.145. The method of claim 134 , wherein the diabetes is type ...

METHODS OF TREATING OVERWEIGHT AND OBESITY

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.

METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbAand reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided. 1. A method for treating diabetes in a human in need thereof , the method comprising administering to the human an effective amount of a sustained release pharmaceutical composition comprising exendin-4 or an exendin analog to achieve a mean steady state plasma concentration of the exendin-4 or the exendin analog of at least 200 pg/ml for at least one month in the human to treat diabetes.2. The method of claim 1 , wherein the sustained release pharmaceutical composition is administered in a continuous mode.3. The method of claim 2 , wherein the continuous mode results from administering the sustained release composition once weekly by subcutaneous injection.4. The method of claim 1 , wherein the sustained release pharmaceutical composition comprises exendin-4.5. The method of claim 1 , wherein the sustained release pharmaceutical composition comprises the exendin analog.6. The method of claim 5 , wherein the exendin analog comprises the amino acid sequence of any one of SEQ ID NOs: 2 and 9-142.7. The method of claim 1 , wherein the sustained release pharmaceutical composition further comprises a sugar.8. The method of claim 1 , wherein the sustained release pharmaceutical composition further comprises a poly(lactide-co-glycolide) copolymer.9. The method of claim 8 , wherein the poly(lactide-co-glycolide) copolymer is purified 50:50 (lactide:glycolide) poly(D claim 8 ,L-lactide-co-glycolide).10. The method of claim 1 , wherein the sustained release pharmaceutical composition comprises 5% (w/w) exendin-4 claim 1 , 2% (w/w) sucrose claim 1 , and 93% (w/w) poly(lactide-co-glycolide)copolymer.11. The method of claim 1 , wherein the sustained minimum plasma concentration of the exendin-4 or the exendin analog agonist is between 200 pg/ml to 350 pg/ml.12. The ...

METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbAand reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided. 1. A method for treating type 2 diabetes in a human in need thereof , the method comprising administering to the human an effective amount of a sustained release pharmaceutical composition comprising 5% (w/w) exendin-4 , 2% (w/w) sucrose , and 93% (w/w) poly(lactide-co-glycolide)copolymer to achieve a mean steady state plasma concentration of the exendin-4 of at least 200 pg/ml for at least one month in the human to treat type 2 diabetes.2. The method of claim 1 , wherein the sustained release pharmaceutical composition is administered in a continuous mode.3. The method of claim 2 , wherein the continuous mode results from administering the sustained release composition once weekly by subcutaneous injection.4. The method of claim 1 , wherein the poly(lactide-co-glycolide) copolymer is purified 50:50 (lactide:glycolide) poly(D claim 1 ,L-lactide-co-glycolide).5. The method of claim 1 , wherein the sustained minimum plasma concentration of the exendin-4 is between 200 pg/ml to 350 pg/ml.6. The method of claim 1 , wherein the exendin-4 is co-administered with metformin claim 1 , a sulphonylurea claim 1 , a thiazolidinedione or any combination thereof.7. The method of claim 3 , wherein 2 mg of the exendin-4 is administered once weekly.8. A method for reducing HbA1C claim 3 , fasting plasma glucose claim 3 , or body weight in a human in need thereof claim 3 , the method comprising administering to the human in a continuous mode an effective amount of a sustained release pharmaceutical composition comprising 5% (w/w) exendin-4 claim 3 , 2% (w/w) sucrose claim 3 , and 93% (w/w) poly(lactide-co-glycolide)copolymer in an amount to achieve a mean steady state concentration of exendin-4 of at least 200 pg/ml for at least one month to reduce HbA1C claim 3 , fasting ...

Compositions and methods for reducing major adverse cardiovascular events

The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or MACE, wherein the treatment reduces the risk of MACE.

Compositions and methods for reducing major adverse cardiovascular events

Exendin for treating diabetes and reducing body weight

EXENDIN FOR TREATING DIABETES AND REDUCING BODY WEIGHT Methods for reducing body weight, altering body composition, treating diabetes, reducing HbAic, and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

EXENDIN FOR TREATMENT OF DIABETES AND REDUCTION OF BODY WEIGHT

METHODS FOR THE TREATMENT OF S

La presente descripción se refiere a composiciones, kits, usos, sistemas y métodos para tratar el sobrepeso y la obesidad, mediante el uso de naltrexona más bupropión, con preferencia, en combinación con un programa integral de control de peso gestionado por internet y/o por vía telefónica y, con preferencia, en sujetos que corren un riesgo mayor de sufrir resultados cardiovasculares adversos.

Exendin for treating diabetes and reducing body weight.

Se proporcionan metodos para reducir el peso corporal, alterar la composicion corporal, tratar la diabetes, reducir HbA1c y reducir el promedio diario de glucosa en la sangre con el uso de exendinas, agonistas de exendina o agonistas de analogo de exendina.

Compositions and methods for reducing major adverse cardiovascular events

The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or MACE, wherein the treatment reduces the risk of MACE.

Compositions and methods for reducing major adverse cardiovascular events.

La presente solicitud se refiere a composiciones, kits, usos, sistemas y métodos para utilizar naltrexona y bupropión o sus sales farmacéuticamente aceptables, con el propósito de reducir el riesgo de padecer desenlaces o eventos adversos cardiovasculares, lo cual incluye los eventos adversos cardiovasculares graves (MACE, major adverse cardiovascular events) en los sujetos, preferiblemente, en aquellos sujetos cuyo riesgo de sufrir desenlaces cardiovasculares adversos o MACE es mayor, que puedan tener sobrepeso o ser obesos. La presente solicitud también se refiere a composiciones, kits, usos, sistemas y métodos para utilizar naltrexona y bupropión o sus sales farmacéuticamente aceptables, en el tratamiento del sobrepeso o de la obesidad en los sujetos, con preferencia, en aquellos sujetos cuyo riesgo de sufrir desenlaces cardiovasculares adversos o MACE es mayor, en el cual el tratamiento reduce el riesgo de MACE.

Methods of treating overweight and obesity

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.

Exendin for treating diabetes and reducing body weight

Compositions and Methods for Reducing Major Adverse Cardiovascular Events

Abstract of the Disclosure The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or MACE, wherein the treatment reduces the risk of MACE.

COMPOSITIONS AND METHODS TO REDUCE SERIOUS CARDIOVASCULAR ADVERSE EVENTS

La presente solicitud se refiere a composiciones, kits, usos, sistemas y métodos para utilizar nalt rexona y bupropión o sus sales farmacéuticamente aceptables, con el propósito de reducir el riesgo de padecer desenlaces o eventos adversos cardiovasculares, lo cual incluye los eventos adversos car diovasculares graves (MACE, major adverse cardiovascular events) en los sujetos. La presente solici tud también se refiere a composiciones, kits, usos, sistemas y métodos para utilizar naltrexona y b upropión o sus sales farmacéuticamente aceptables, en el tratamiento del sobrepeso o de la obesidad en los sujetos.

Exendin for treating diabetes and reducing body weight

Methods To Treat Diabetes And Reduce Body Weight

MéTODOS PARA TRATAR DIABETES E REDUZIR O PESO CORPORAL. A presente invenção refere-se a métodos para reduzir o peso corporal, alterando a composição do corpo, tratar diabetes, reduzindo HbA1~c~ e reduzir a média diária de glicose do sangue pelo uso de exendinas, agonistas de exendina ou agonistas análogos de exendina. METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT. The present invention relates to methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1-c- and reducing the average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists. .

Methods of treating overweight and obesity

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.

Methods of treating overweight and obesity

【課題】有害な心血管アウトカムのリスクが増大している対象における過体重または肥満の効果的な治療を提供する【解決手段】本開示は、ナルトレキソン+ブプロピオンを、ウェブをベースおよび/または電話をベースにした包括的体重管理プログラムと好ましくは組み合わせて使用して、好ましくは有害な心血管アウトカムのリスクが増大している対象における過体重および肥満を治療するための組成物、キット、使用、システム、および方法に関する。【選択図】なし

Exendin käytettäväksi diabeteksen hoidossa ja ruumiin painon vähentämiseksi

Exendin for use in treating diabetes and reducing body weight

Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt

Composiciones y metodos para reducir eventos adversos cardiovasculares graves.

La presente solicitud se refiere a composiciones, kits, usos, sistemas y métodos para utilizar naltrexona y bupropión o sus sales farmacéuticamente aceptables, con el propósito de reducir el riesgo de padecer desenlaces o eventos adversos cardiovasculares, lo cual incluye los eventos adversos cardiovasculares graves (MACE, major adverse cardiovascular events) en los sujetos, preferiblemente, en aquellos sujetos cuyo riesgo de sufrir desenlaces cardiovasculares adversos o MACE es mayor, que puedan tener sobrepeso o ser obesos. La presente solicitud también se refiere a composiciones, kits, usos, sistemas y métodos para utilizar naltrexona y bupropión o sus sales farmacéuticamente aceptables, en el tratamiento del sobrepeso o de la obesidad en los sujetos, con preferencia, en aquellos sujetos cuyo riesgo de sufrir desenlaces cardiovasculares adversos o MACE es mayor, en el cual el tratamiento reduce el riesgo de MACE.

Συνθεσεις και μεθοδοι για τη μειωση μειζωνων ανεπιθυμητων καρδιαγγειακων συμβαντων

Η παρούσα αίτηση σχετίζεται με συνθέσεις, κιτ, χρήσεις, συστήματα και μεθόδους χρήσης ναλτρεξόνης και βουπροπιόνης, ή φαρμακευτικώς αποδεκτών αλάτων τους, για τη μείωση του κινδύνου ανεπιθύμητων καρδιαγγειακών εκβάσεων ή συμβάντων, συμπεριλαμβανομένων μείζονων καρδιαγγειακών συμβάντων (MACE) σε υποκείμενα, κατά προτίμηση εκείνα που βρίσκονται σε αυξημένο κίνδυνο ανεπιθύμητων καρδιαγγειακών εκβάσεων ή συμβάντων ή MACE, τα οποία μπορεί να είναι υπέρβαρα ή παχύσαρκα. Η παρούσα αίτηση επίσης σχετίζεται με συνθέσεις, κιτ, χρήσεις, συστήματα και μεθόδους χρήσης ναλτρεξόνης και βουπροπιόνης, ή φαρμακευτικώς αποδεκτών αλάτων τους για την αγωγή υπερβολικού βάρους ή παχυσαρκίας σε υποκείμενα, κατά προτίμηση με αυξημένο κίνδυνο ανεπιθύμητων καρδιαγγειακών εκβάσεων ή συμβάντων ή MACE, όπου η αγωγή μειώνει τον κίνδυνο MACE.

Methods of treating overweight and obesity

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.

Eksendyna do stosowania w leczeniu cukrzycy i zmniejszania masy ciała

Exendin za uporabo pri zdravljenju sladkorne bolezni in zmanjševanju telesne teže

Eksendino naudojimas diabeto gydymui ir kūno svorio mažinimui

Exendina para su uso en el tratamiento de la diabetes y la reducción del peso corporal

Se proporcionan métodos para reducir el peso corporal, alterar la composición corporal, tratar la diabetes, reducir la HbA y reducir la glucosa en sangre diaria promedio mediante el uso de exendinas, agonistas de exendina o agonistas análogos de exendina. (Traducción automática con Google Translate, sin valor legal)

Εξενδινη για θεραπευτικη αγωγη διαβητη και μειωση σωματικου βαρους

Παρέχονται μέθοδοι για μείωση σωματικού βάρους, αλλαγή σωματικής σύστασης, θεραπευτική αγωγή διαβήτη, μείωση HbA1C και μείωση μέσης ημερήσιας γλυκόζης αίματος χρησιμοποιώντας εξενδίνες, αγωνιστές εξενδίνης ή αγωνιστικά ανάλογα εξενδίνης.

Συνθεση για χρηση σε μια μεθοδο θεραπειας υπερβολικου βαρους και παχυσαρκιας σε ασθενεις με υψηλο καρδιαγγειακο κινδυνο

Η παρούσα ανακοίνωση αφορά συνθέσεις, κιτ, χρήσεις, συστήματα και μεθόδους για την θεραπεία των υπέρβαρων και παχύσαρκων με χρήση ναλτρεξόνης και βουπροπιόνης, κατά προτίμηση σε συνδυασμό με ένα ολοκληρωμένο πρόγραμμα διαχείρισης του βάρους, μέσω του διαδικτύου ή/και μέσω του τηλεφώνου και προαιρετικά σε άτομα με αυξημένο κίνδυνο δυσμενών καρδιοαγγειακών εκβάσεων.

Composiciones de liberacion sostenida de naltrexona y bupropion para usarse en el tratamiento de sobrepeso y obesidad.

La presente descripción se refiere a composiciones, kits, usos, sistemas y métodos para tratar el sobrepeso y la obesidad, mediante el uso de naltrexona más bupropión, con preferencia, en combinación con un programa integral de control de peso gestionado por Internet y/o por vía telefónica y, con preferencia, en sujetos que corren un riesgo mayor de sufrir resultados cardiovasculares adversos.

Methods of treating overweight and obesity

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increases risk of adverse cardiovascular outcomes.

Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt